Access the full text.
Sign up today, get DeepDyve free for 14 days.
Rae-Ellen Kavey, D. Simons-Morton, Janet Jesus (2011)
Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary ReportPediatrics, 128
M. Oliver, J. Heady, Jeremy Morris, J. Cooper (1980)
W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up.The Lancet
A. Alsheikh-Ali, P. Maddukuri, Huixian Han, R. Karas (2007)
Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials.Journal of the American College of Cardiology, 50 5
D. Graham, J. Staffa, D. Shatin, S. Andrade, Stephanie Schech, L. Grenade, J. Gurwitz, K. Chan, Michael Goodman, R. Platt (2004)
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.JAMA, 292 21
J. Kevill (2012)
ADHD Drugs and Serious Cardiovascular Events in Children and Young AdultsYearbook of Neurology and Neurosurgery, 2012
Allen Taylor, T. Villines, E. Stanek, P. Devine, Len Griffen, Michael Miller, N. Weissman, M. Turco (2009)
Extended-release niacin or ezetimibe and carotid intima-media thickness.The New England journal of medicine, 361 22
P. Barter, M. Caulfield, M. Eriksson (2008)
Effects of torcetrapib in patients at high risk for coronary eventsJournal of Vascular Surgery, 47
Trilipix (fenofibric acid): drug safety communication: label change.
M. Juonala, C. Magnussen, G. Berenson, A. Venn, T. Burns, M. Sabin, S. Srinivasan, S. Daniels, P. Davis, Wei Chen, Cong Sun, M. Cheung, J. Viikari, T. Dwyer, O. Raitakari (2011)
Childhood adiposity, adult adiposity, and cardiovascular risk factors.The New England journal of medicine, 365 20
J. Brugts, T. Yetgin, S. Hoeks, A. Gotto, J. Shepherd, R. Westendorp, A. Craen, R. Knopp, H. Nakamura, P. Ridker, R. Domburg, J. Deckers (2009)
The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trialsThe BMJ, 338
VIEWPOINT ONLINE FIRST Scan for Author Audio Interview Universal Screening and Drug Treatment of Dyslipidemia in Children and Adolescents sion of treatment to intermediate-risk persons. As a result of Bruce M. Psaty, MD, PhD these findings and recommendations, the use of statins and Frederick P. Rivara, MD, MPH their indications have expanded. By 2005, an estimated 30 mil- lion Americans were taking statins, and in 2009, both simva- VER THE LAST FEW DECADES, THE THEORY THAT statin and atorvastatin were among the top 5 products dis- adult diseases begin in childhood has been widely pensed. The expert panel’s recommendations for the use of discussed. Smoking, the most common underly- drugtherapiesinchildrenaresimplypartofthishistoricaltrend. Oing cause of death for adults in the United States, Both the expanded use of statins in new populations and the begins before the age of 18 years in the majority of adult smok- effort to achieve additional lipid lowering in high-risk patients ers. Obesity has become the largest health problem in the increase the opportunities for benefits and for harms. United States, and the difficulty of long-term weight loss for As a drug class, the statins are not harmless. For in- obese children and adolescents means that many
JAMA – American Medical Association
Published: Jan 18, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.